Epco, Zanu, Ritux for R/R FL or MZL

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Mar 1, 2028 → Mar 1, 2030
Primary endpoint reworded 1 of 2 changed
See other at-risk trials from Reid Merryman, MD

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 1, 2028 to Mar 1, 2030 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 45 → 71 participants
    • Study completion pushed from Mar 1, 2030 to Mar 1, 2032
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: details revised at 12 of 16 entries
    • Study description revised
  2. Study sites: 2 to 3v5
  3. Study sites: 1 to 2
    • Study title shortened, about 14 words
    v4
  4. Enrollment target: 24 to 45v3 Show 9 more changesShow less
    • Primary completion date: Mar 1, 2027 to Mar 1, 2028
    • Primary endpoints: 1 to 2
    • Study sites: 2 to 1
    • Study completion date: Mar 1, 2029 to Mar 1, 2030
    • Eligibility criteria expanded, about 88 words
    • Secondary endpoints: details revised at 9 of 16 entries
    • Study description expanded, about 49 words
    • Study title expanded, about 9 words
    • Study arms: 1 to 2
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2025 to Jan 21, 2025
    • Site details revised at 2 of 2 sites
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
Trial Details
NCT Number NCT06563596
Lead Sponsor Reid Merryman, MD
Collaborators: BeiGene, Genmab
Conditions
(from sponsor)		 Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
Related terms Lymphoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov